Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for bronchiolitis obliterans syndrome after lung transplantation
2014-002022-12Phase 2Completed
- Sponsor
- Copenhagen Trial Unit
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pirfenidone in Bronchiolitis Obliterans Syndrome (BOS) and Bronchiolitis Obliterans (BO) (2 arms), sponsored by Copenhagen Trial Unit. Primary endpoint: Change in FEV1 from baseline to 6 months. Started Oct 2014; status: completed.
02
Drugs
pirfenidone
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)Bronchiolitis Obliterans (BO)
Beyond the preview
Go deeper on 2014-002022-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002022-12.